lifeeasy

Transcription

lifeeasy

LifeLines
For the Southern California Life Science Community
10
New Year Brings New Policy
Challenges for Biocom
13
Ten Reasons You Should Attend
an Event
22
Our 2014 New Year’s Resolutions
patients
more
approach
venture
better
inspirational
genetic
dialog
medicine
drugs
opportunity
international
amount
successful
close
healthcare
digital health
working
big
lot
way
important
unique
event
jobs
high
data
little
company
provides
personalized
research
investors
consumers
drive
need
initial
based
annual
situation
many
life
begin
drive
open
critical
set
markets
2014
market
large
effects
best
think
become
even
ideas
start
outcomes
make
partners
moving
February
field
premium
many
together
saw window health trying passion
cost
going
conference
long
next
steady
significant
moving
funds
changes
disease
pharma
insurance
population
years
others
ahead
therapy
diagnostic
technologies
early
competition
sequence
profile
term
low
required
identify
planning
providing
right
value
deal
science San Diego life science
phase
benefits
innovation
example
stream
FDA
look
system
through
support
response
support
underway
year
develop
high
including
using
reduced
access
feast
robust
medical
results
found
warranted
new
employees
creative
forward
good
real
energy
funding
defined
research
office
quality
come
available
capital
clinical
much forces products
biotech
individual
development
use
find
sharing
tailored
rest
part
still
molecular
Volume 23, Issue 1 S p r i n g 2 0 1 4
open
see
over
first
price
treat
impact
sector
pipeline
issues
take
stage
information
allows
given
past
space
many
business
time
precision
now
energy
government
continue
one
answer
ways
maintain
greater
close
help
trend
hope
world
change
non
pharmaceutical
seeing
costs
IPO care
those
making
top remain
products
specific
resources
life
easy
pricing
largest
Genomatica has relied on the C&W Life Sciences team as its real
estate advisor for years. Throughout our early years, C&W negotiated
very flexible terms and rights. These same rights later allowed us the
flexibility for an early exit and the ability to negotiate great pricing and
terms for our new headquarters building. With their help, we secured a
custom designed project which highlights our science and positions us for
success. I highly recommend them to other life science companies.
Christophe Schilling, CEO, Genomatica, Inc.
SUCCESS STARTS WITH HIRING THE
RIGHT REAL ESTATE REPRESENTATION
From start-ups to large pharmaceutical companies, we have an unsurpassed level of
experience in advising and negotiating the best possible terms for your next laboratory
facility. For the past 30 years, we have focused our career on helping companies like
yours, find and negotiate leases on facilities that enhance the human experience, foster
collaboration and innovation, and help attract and retain the best and brightest talent.
Let us be your partner in success.
See what we can do for you: www.sdlifesciences.com
(858) 452-6500
BRENT JACOBS
GREG BISCONTI
TED JACOBS
CA LICENSE NO. 791657
WELCOME
I n T h is I ss u e
By Joe Panetta,
President and CEO, Biocom
2 Cover Story: I see.... 2014
10Public Policy : New Year Brings New Policy
Challenges for Biocom
11Members in Action: HR Conference, Breakfast
Meeting
12Members in Action: Annual Celebration of Life
Dinner
13Events: Ten Reasons You Should Attend an Event
16Guest: San Diego Public Companies to Watch in
2014
18The San Diego Festival of Science & Engineering
- Be there!
20 Biocom Institute: Life Science Summer Institute
Celebrates 10th Anniversary of Developing a
Workforce Pipeline
22Biocom Purchasing Group: Our 2014 New Year’s
Resolutions
24Premium Member Spotlights:
Fisher Scientific, GE Healthcare Life Sciences,
Janssen Labs, Wilson Sonsini Goodrich & Rosati
27 Biocom Board and Committees
28 Biocom Membership
E d i to r : Jennifer Landress
CO P Y E d i to r : Josh Baxt
DESIGN & LAyout: Arlene Arreola
V o l u m e 2 3 , I ss u e 1
Biocom, a member driven
organization is here to assist life
science companies like yours
to fulfill your most ambitious
goals. We can help your
company with saving money,
advocacy, increased visibility,
networking opportunities,
capital development and
workforce development. To
learn more visit us at www.
Biocom.org
Good News
Welcome to our Spring 2014 edition of LifeLines. In this issue, we focus on
expectations for 2014 from the perspectives of both the Biocom staff and the
industry members we serve.
I am particularly encouraged after attending the annual JP Morgan Health
Care Conference in January. The climate was more upbeat than ever regarding
the future of the life science industry. The conference highlighted large
pharma’s growing focus on developing biological products, as well as their
significant advances in creating research tools and diagnostics—successes
that will serve Southern California well. So, on this positive note, I know you’ll
enjoy our cover story on predictions for 2014 as much as I did.
Biocom had a very successful 2013 on the advocacy front, opening our
Washington D.C. office and leading the California life science community’s
Sacramento public policy efforts with our partners BayBio and CHI. This year
brings a new set of challenges, such as lobbying for increased NIH funding,
ensuring a positive regulatory climate in California and working with our new
San Diego mayor. These are discussed by our veteran vice president of Public
Policy, Jimmy Jackson.
Biocom has always been known for our aggressive and timely schedule of
networking events and conferences. As you will read, the kick-off for our year is
the highly successful annual Global Partnering Conference. In this issue, we’ll
share the top 10 reasons to attend our events and conferences throughout the
year. These events are designed to appeal to every level of your organization.
One of my favorite yearly events is the San Diego Festival of Science &
Engineering, during which our companies and research institutes provide an
opportunity for people throughout our community to learn more about life
science and engineering, with a special focus on students. On that note,
Liisa Bozinovic, the new Executive Director for the Biocom Institute has an
article on the celebration of the 10th anniversary of the Life Science Summer
Institute, a program that has been very successful in providing internships in
life science companies for our local high school and college students.
On the membership side, I’m pleased that Biocom enlisted 120 new
members in 2013, bringing our total membership to almost 600 firms. You’ll
get a sneak peek at the new concierge program Biocom has created for our
members to ensure that we continue to inform them about the multi-faceted
benefits of Biocom membership.
Finally, our regular columnist Mandy Jackson rounds out our theme of
predictions for 2014 with an article on top companies to watch. Given the
diversity and depth of the life science sector that we serve, it’s difficult, if not
impossible, to forecast success, but I know that you’ll find these cutting edge
companies and their technologies intriguing. We’ll follow their progress, along
with you, as we work to accelerate your success.
www.Biocom.org
Biocom LifeLines Spring 2014
1
Cover Story
I See...2014
Southern California’s Life Science Leaders
Give their Insight on what to expect in 2014
The mood on the ground at the JPMorgan Healthcare Conference held in San Francisco each January
sets the tone for the industry for the year. This year, people were downright cheerful as they basked in the
unseasonably warm sunshine in Union Square. While the year looks positive from an IPO perspective,
the overall forecast remains cloudy, as our industry grapples with the looming changes of the Affordable
Care Act and an uncertain payer environment. In light of this uncertain forecast, Biocom asked Southern
California leaders about their outlook for 2014 and what big trends they see impacting our industry this
year. In the following pages read what they had to say.
going
flexibility
much more
extremely promising to see how science’s growing knowledge of genetics is
beginning to have a meaningful and actionable impact on oncology
financing quality
for
think
there
to
Strategic venture capital
funds will continue to
be the leading force in
the industry, however, as
liquidity is achieved via
public markets, financial
venture funds will make
a comeback, late in the
year and early in 2015.
oncology
in
see
be
with respect to “popular” indications, cancer
therapeutics should continue to be front and
center, with immunotherapies, especially antibody
technologies, personalized medicine and stem cells
also taking a leading role in the industry
promising
science’s
extremely
companies
is
beginning
It’s
actionable
and
Strategic venture capital funds will continue to be the
leading force in the industry, however, as liquidity is
achieved via public markets, financial venture funds will
make a comeback, late in the year and early in 2015.
how
growing
genetics
knowledge
have
This year partnering will become even more
important and we’ll be seeing more deal structures
that are creative and tailored to the situation
meaningful
impact
patients
more
e
s
successful
robust
medical
underway
using
close
system
healthcare
d
h
deal
including
high
jobs
data
Cover Story
little
example
sequence
company
provides
It will be challenging.
To justify premium pricing, biotechnology companies are all
personalized
trying to find
differentiated drugs that have a significant impact
planning
in patients. These are not easy to
come by, so naturally the
drive
competition is very intense, and you have to go further upstream
stream
Of the dominant disruptive forces
to have access to quality innovations at a reasonable price. This
phase
profile
research
should result in more early-stage deal making in the
years to come.
consumers
that are currently in play in healthcare,
open
critical
providing
right
identify
Magda Marquet, Ph.D.
Founder and Co-chairman,
Althea Technologies
Executive Chair, Biocom Board of
Directors
working
benefits
low
required
event
investors
annual
drive
situation
many
begi
need
one of the most formidable is the trend
Carin Canale
initial
towards individualized medicine using
President, Canale Communications,
tools such as pharmacogenomics. Although we have been talking
Vice Chairwomen, Biocom Board of
about it for over a decade and despite the fact that there are a few
Directors
make
examples in oncology and cardiovascular disease, the main impact
Open. Close. Open. Close? The back
moving
is still to come. With the staggering number of over 4 billion new
and forth banter on the state of the IPO
prescriptions written in 2012, the need to prescribe drugs using the
window at the end of 2013, reminded me
premium
February
pharmacogenetic profile of the patient could not be more pressing.
of my daughter wanting the car window
In the last couple of years the FDA itself has stepped in and listed
open – her mind changes with the wind
over 200 drugs with pharmacogenomics information on their
every five seconds. As 2013 came to a
diagnostic
labels. There is little doubt that the impact of pharmacogenomics
maintain
close, while some predicted the end of
the biotech IPO opportunity,
on the elderly patient population will be profound. Consider
I was steady with my forecast of an open and robust window for life
these two facts: adverse drug reactions are among the top five
science companies
greatest threats to the health of seniors and on
in 2014.
On
average, seniors take 14 (ages 65 to 69) to 18 “what I predict is that there will be a steady
the heels of the
(ages 80significant
to 84) prescriptions per year often
drumbeat of IPOs and the best ideas – and only the annual JP Morgan
concomitantly
(seniors in nursing homes take
conference,
moving
best ideas – for new medicines or other medic al
on average 13 different prescriptions per day).
it
seems
the
By alerting the physician on a given patient’s
sentiment is now
innovations will be welcomed withinformation
open arms.”
or absorb a given drug,
good
hanges ability to metabolize
quite unanimous
— C arin C anale
available
pharmacogenomics will help
millions avert life
– the window will sector
threatening and costly hospitalizations.
remain open and
term
big
based
set
life
markets
2014
market
partners
large
effects
best
think
become
even
ideas
start
outcomes
field
many
ether
passion
window
health
trying
saw
technologies
unds
quality
ase
h
l
r
real
energy
funding
defined
research
s
t
ahead
therapy
government
continue
come
capital
sharing
Diego Miralles,
M.D.
Global Head, Innovation,
Janssen Pharmaceuticals
clinical
allows
given
rest
office
products
use
find
part
precision
past
space
take
open
treat
impact
many
stage
world
change
help
companies are standing in line to go public.
The question is how many and for how long? Nobody knows the
answer, but what I predict is that there will be a steady drumbeatnon
pharmaceutic
of IPOs and the best ideas – and only the best ideas – for new seeing
medicines or other medical innovations will be welcomed with open
arms. What I don’t think we’ll see is the irrational exuberance of
the genomics bubble, rather a market where the highs may not be
as high, but the lows aren’t nearly as low. I those
for one am not a fan of
feast or famine. I think we’ve matured as an industry and my hope
for 2014 is that the market will support only those companies with
real data and real opportunity for value.
products
over
first
one
answer
pipeline
see
issues
right now based on the fact that the IPO
window is open, valuations have gone up
and investors are returning to the space.
Never has there been better science.
We are entering into therapeutic spaces
and modalities that we never would have
dreamed of. I really believe the possibilities are endless.
A big change is the impact of molecular diagnostic in cancer.
Like we have been long doing in infectious diseases, we can
identify the ways
drugs needed to treat that specific molecular change.
This results in reduced toxicity, better outcomes and price
reduced
unnecessary still
costs. With a more rational use of drugs, we will have
a better value proposition than we have in the past.
A big question is how quickly the system will evolve with regard
to how we pay for healthcare. In the U.S. we are still able to obtain
premium drug pricing that would be difficult to get anywhere else
in the world. However, given the fiscal situation, how can the U.S.
sustain that differential price relative to the rest of the world?
now
business
time
tailored
There is a lot of energy in the industry
energy
greater
close
trend
hope
costs
IPO care
making
top remain
specific
resources
life
Rich Heyman, Ph.D.
President & CEO, Seragon
pricing
Pharmaceuticals
I think for quality companies there
largest
is going to be much more flexibility in
financing, and, as a CEO of a private
company, my options are much greater
than they were in the past.
Last year the strong companies went
out at reasonable valuations and have
increased in value over time. These companies have access to
3
easy
patients
more
successful
robust
medical
deal
including
underway
using
Cover Story
low
required
identify
event
high
jobs
data
little
example
San Diego life science
“We are seeing greater patient
engagement
science
healthcare
and empowerment, and I think that trend
close
system
sequence
working
will continue
through and beyond 2014.”
stream
— Hillary Theakston
phase
profile
benefits
right
open
research
critical
providing
company
provides
begin
whistleblowers and issues under the Foreign Corrupt Practices Act
(FCPA) and the Sunshine Act, for example, means that companies
will needpersonalized
to ensure they have strict risk and compliance programs
annual
planning
in place to avoid serious chargesdrive
and damaging allegations in the
future.
consumers
situation
Executive Director, The Clearity
Hillary Theakston
many
investors
need
drive
Foundation
much more capital than they have in the last few years, putting
initial
them in an interesting position. Previously there were minimal
We are seeing greater patient
opportunities for an exit—only M&A. The IPOs offer a potential
engagement
and
empowerment,
liquidity event for investors and puts the management team in the
make
and I think that trend will continue
moving or continue to go it alone because they
position to either partner,
through and beyond 2014. People are
have enough capital to fund later stage programs. This is a great
becoming more personally involved in
February
thing because with this business, which ispremium
a hard business, you
healthcare coverage decisions, now that
want as much flexibility and optionality as possible. Because of
the Affordable Care Act facilitates online access to insurance
this, the mood in the industry is quite upbeat, and I don’t think
information. Patients are flocking to online communities and using
that the doors are going to slam shut any time soon.
diagnostic social networks to obtain health information and to share their
maintain
However, a concern I have is that weaker companies may try to
experiences to help others. Through traditional and social media,
go public, and I hope that doesn’t spoil the market. It is important
patients are learning about discoveries that may dramatically
that public investors do enough homework to separate between the
change treatment. We are shifting from a one-size-fits-all approach
wheat and the chaff in a meaningful way. Another thing I get a little
to more personalized one. This trend will converge with more
worried
about is whether the investors are going to begin investing
significant
empowered patients, who will not only demand improved health
more in early stage companies again. It’s going to be important to
outcomes, but better value for their healthcare dollar.
moving
have venture
capital firms, both private and corporate, investing in
early stage technologies or the pipeline will dry up.
Harry Gruber, M.D.
President & CEO, Tocagen
information
good
nges
Lisa Haile, J.D., Ph.D.
I believe that cancer immunotherapy
available
Partner, Co-Chair, Global Life Sciences
will continue to make importantsector
Sector, DLA Piper
advances this year, and ultimately lead
help
Vice President & General Counsel,
to a fundamental shift in the treatment
sharing
Biocom Board of Directors
of cancer. This shift is reminiscent of
non
Following the annual JP Morgan
pharmaceutical
the dramatic progress against infectious
defined
Healthcare
conference in San Francisco
tailored
disease after the introduction of vaccines.seeing
the week of January 12, several trends
While the invention of antibiotics was a
for 2014 percolated to the top. First,
huge leap forward in treating pathogens, infectious diseases were
for the second year in a row, the mood
only truly tamed with the advent of vaccines that elicit an immune
those
was upbeat and industry leaders appear optimistic for a successful
response against the pathogen. In the same way, while small
2014. The IPO class of 2013 was one of the largest in biotech
molecule drugs can be highly effective at killing cancer cells, the
history with over 30 companies going public and 2014 should see
most important way to treat cancer will be invigorating the immune
the trend continue, assuming positive data and a low incidence products
system to recognize and eliminate cancer cells.
of clinical failures, which tend to rattle investors. Second, with
Cancer immunotherapeutics is finally coming of age with the
respect to “popular” indications, cancer therapeutics should
approval of ipilimumab for treating melanoma, Science naming
continue ways
to be front and center, with immunotherapies, especially
cancer
immunotherapy as the “Breakthrough of the Year” for
pricing
antibody technologies, personalized medicine and stem cells also
2013, and the PD-1/PD-L1 targeting antibodies racing towards
price
taking a leading role in the industry. In addition, RNA technologies,
largest
approval. An additional
technology involves CAR T cells, which uses
still
such as RNA interference (RNAi), should become more palatable
gene therapy to reprogram patients’ T cells to target and destroy
for investors in 2014, especially with the development of new
lymphoma cells. Other companies, including Tocagen, are also
and successful delivery systems which have been needed for this
using gene therapy to harness the immune system to treat cancer.
field to take off. Finally, compliance and transparency have been
Our approach involves a tumor-selective retroviral replicating vector
and will continue to be key issues for global companies in 2014.
that delivers a therapeutic gene for an initial local antitumor effect
The increase in internal and government investigations involving
followed by a specific, systemic antitumor immune response. Our
term
big
based
set
life
markets
2014
market
partners
large
effects
best
think
become
even
ideas
start
outcomes
field
many
ether
passion
window
health
trying
saw
ahead
therapy
technologies
nds
quality
se
real
energy
funding
research
come
capital
clinical
rest
office
products
use
find
4
part
government
continue
allows
given
take
open
treat
impact
over
first
one
answer
pipeline
see
issues
past
space
now
many
business
time
precision
energy
greater
close
stage
trend
hope
world
change
costs
IPO care
making
top remain
specific
resources
life
easy
more
close
system
healthcare
working
sequence
company
provides
planning
personalized
Cover Story
annual
drive
open
stream
lead product, Tocaphase
511, initially kills theprofile
tumor by converting a
prodrug into a potent
anticancer
agent
within
the cancer cell.
providing
These dying tumor cells then selectively stimulate the immune
system to seek and destroy remaining cancer cells. This, and our
other immunotherapy programs in development at our company in
addition to alternative approaches at other companies, have the
potential to become dramatically better tools in the fight against
moving
cancer.
begin
Standish Fleming
consumers
Managing Member and
Owner, Forward
many
situation
Ventures
The IPO window will close. I know,
initial
that sounds like a no-brainer, but in
some ways this window, the first under
make
the JOBS act, really has been different.
As skeptical as I am about Washington’s
ability to do anything economically
premium
February
constructive, they got this one right.
Damien McDevitt, Ph.D.
VP & Head of BD for R&D Extended
I’m not sure it has done anything for jobs, but JOBS has greatly
Therapy Areas, Head of R&D West Coast
improved the efficiency of the IPO process. The result has been a
Satellite Office, Worldwide Business
diagnostic better selection of companies, more accurate pricing and a more
maintain
Development, GlaxoSmithKline
durable window. But, while JOBS improves the process, those
The pharma industry has gotten a lot
details do not drive the system. As the Fed takes away the freeof heat in recent years about its lack of
money punch bowl, Wall Street will sober up and the window will
R&D productivity and innovation and the
close, gradually, I hope.
drought of new medicines available to
significant
In 2014 we will begin to feel the full effects of Obama Care, and
patients. That criticism, much of which
they will not be good for biotech or innovation. Having fumbled
movinghas led to a fair amount of soul searching about how,
was warranted,
the Affordable Care Act kick-off (the easy part), the political
and with whom, we develop new medicines. The conclusion many
establishment will now try to actually play the game (the hard part).
of us have come to is that all of the available best science can’t
The burden on the information
Federal budget will result in a shift of national
nges be foundgood
within our company walls and that we must significantly
healthcare
priorities
from investment (research) to consumption
available
increase access to external scientific and medical innovation to
sector
(services for 20-30 million additional enrollees). A thought for
maintain a sustainable pipeline of novel medicines for patients.
the paranoid: if the game doesn’t gohelp
better than the kick-off,
To do this, many large pharmas
are joining forces with a broad
sharing
Obama Care might be the prelude to a single-payer system—a low
range of scientists in academia, biotech, venture firms and even
probability event but truly scary for biotech.
non
other pharma companies and we saw a lot of this activity in 2013.
pharmaceutical
defined
This year partnering will become
even more important and we’ll be
seeing
tailored
“Working in creative ways with partners
seeing more deal structures that are creative and tailored to the
and constructively managing relationships
situation.
A significant area of evolution is pharma’s relationship with
will be critic al to developing
the next
those
venture capital. Many pharmas, including GSK, have become
generation of medicines for patients who
limited partners in venture funds. Moving forward you will see
even more creative pharma-VC relationships develop. GSK has
are waiting.”
established a unique discovery collaboration model with Avalon products
— DAMIEN MCDEVITT
Ventures to build up to 10 project-based companies together,
sharing ideas and providing access to GSK technologies and
Jay Lichter
resources.
ways
pricing
Managing Director, Avalon Ventures
Working in creative ways with partners and constructively
price
largest Last year saw the opening of the
managing relationships will be critical to developing the next
still
IPO window for the first time in years,
generation of medicines for patients who are waiting. To do so it is
and 2014 will continue to show strong
critical to be where your partners are, which is why GSK set up a
public market support for life science
satellite office in San Diego in January 2014.
companies. Additional IPO’s and followon financings will drive the broader
market as newly public companies will
look to expand their product offerings via
licensing and M&A. The venture capital market will only slightly
return in 2014. Strategic venture capital funds will continue to be
the leading force in the industry, however, as liquidity is achieved
via public markets, financial venture funds will make a comeback,
late in the year and early in 2015.
benefits
right
critical
investors
term
big
research
based
set
drive
need
life
markets
2014
market
partners
large
effects
best
think
become
even
ideas
start
outcomes
field
many
ether
ahead
therapy
technologies
nds
quality
se
real
energy
funding
esearch
office
come
capital
clinical
products
use
find
part
rest
government
continue
allows
given
take
open
treat
impact
over
first
one
answer
pipeline
see
issues
past
space
now
many
business
time
precision
energy
greater
close
stage
trend
hope
world
change
costs
IPO care
making
top remain
specific
resources
life
easy
5
patients
more
successful
robust
medical
deal
including
underway
using
Cover Story
close
system
healthcare
low
required
identify
event
high
jobs
data
sequence
company
provides
The relationship between pharma and venture capital firms
and venture-backed companies should remain on new more even
personalized
footing, because of the robust public markets. However, public
“2014
will be the year that Connected
planning
markets can be fickle and change quickly. When this happens,
turns the corner.” drive
venture capital and biotech
companies
will
need
to
be
self-reliant
stream
— JACK FLORIO
again. Hopefully, this
won’t happen in 2014.
phase
profile
working
benefits
right
open
research
critical
providing
little
example
Health
annual
consumers
drive
situation
many
begin
need
Steven Mento
President & CEO, Conatus
initial
Pharmaceuticals
disease, their own bodies and how to restore and maintain health.
What’s happened over the last decade
Another driver is the change in the healthcare system that pushes
is that large pharmaceutical companies
makeof the cost and the decision-making responsibility onto the
more
movinghave increasingly looked to smaller
consumer driving him or her to become more educated buyer and
drug development companies for their
concerned about maintaining their health to lower their costs.
pipeline opportunities.
Fewer companies
premium
February
We will start to see an even greater integration of the biotech and
advance drugs all the way from concept
pharmaceutical products of our Biocom members with the apps,
to market independently. I think what
technologies, and devices of the tech world working together with
little companies do really well is focusing on trying to get it
right
diagnostic
the focus on improving outcomes. maintain
in the early stages. If they are successful with the preclinical and
San Diego is in a unique position to establish itself as the
clinical development of their products, they or their products often
epicenter of this rapidly emerging market with the strength of
are acquired by larger companies which then advance through
organizations like Biocom, Qualcomm, WLSA, West Health, Scripps
regulatory approval to commercialization. That’s neither good nor
Translational Science Institute and too many others to mention
bad, but
does reflect the new reality in our industry.
all working together with the common goal of demonstrating
significant
This new reality provides a tremendous opportunity for San
leadership in how healthcare is delivered to the consumer and
moving
Diego. We
have the entrepreneurial environment, infrastructure
more importantly how health is maintained.
and resources – excellent research institutions and universities,
venture-backed funding, as well as good trade organizations and
Mark Stevenson
information
good
nges support networks
– to facilitate the startup and growth of life
Executive Vice President, Thermo Fisher
available
Scientific & President, Life Sciences sector
sciences companies. What’s special about San Diego, however, is
Solutions
the sense of community. People are extremely supportive. We don’t
help
It’s extremely
promising to see how
look at other companies as competitors.
They’re part of the family
sharing
science’s
growing
knowledge of genetics
of biotech in the San Diego region. I think that’s the reason we
non
is beginning to have a meaningful and
pharmaceutical
have so many companies positioning themselves in this industry
defined
actionable impact on oncology. Ourseeing
in this location.
tailored
ability today to rapidly peer into the DNA
of cancerous tumors through sequencing
Jack Florio
CEO, Amplyx Pharmaceuticals
technology and accurately identify specific driver mutations with
those
2014 will be the year that Connected
the aid of cancer panels is changing how
oncologists treat the
Health turns the corner.
We will
disease – at a very individualized level. But there is yet another
begin to leave behind an environment
evolving segment of the personalized medicine market that rivals
with a collection of individual apps, products
the growth we’ve seen in oncology, and which we have every reason
technologies, and devices that populate
to look forward to in the years ahead.
consumers smart phones, computers,
Pharmacogenomics (PGx) is poised to become a booming
and phones. We are now moving into an
business
ways
pricingthat also leverages genetics and sophisticated
environment where all of this technology
instruments, but with more immediate application. Currently,
price on
starts to become integrated into healthcare solutions focused
there are about 70largest
drugs on the market to treat conditions ranging
improving still
outcomes and lowering costs. This market will have
from cardiovascular disease, depression and chronic pain, but how
moved from a B2C market to a B2B2C market where the adoption
can doctors discern which will work best for their patients? Similar
will be driven by payors who will be demanding demonstrated
to the revolution we’re seeing in oncology, PGx leverages genetics
outcomes.
to help doctors prescribe the right drug to the right patient. This
One key driver of this is the democratization of health care where
is great news for patients, who otherwise may be given a drug that
consumers now possess a significant amount of information about
isn’t compatible with their genetic makeup, but it’s also good for
investors
term
big
based
set
life
markets
2014
market
partners
large
effects
best
think
become
even
ideas
start
outcomes
field
many
ether
passion
window
health
trying
saw
ahead
therapy
technologies
nds
quality
se
real
energy
funding
research
come
capital
clinical
rest
office
products
use
find
6
part
government
continue
allows
given
take
open
treat
impact
over
first
one
answer
pipeline
see
issues
past
space
now
many
business
time
precision
energy
greater
close
stage
trend
hope
world
change
costs
IPO care
making
top remain
specific
resources
life
easy
more
close
system
healthcare
working
sequence
planning
right
critical
big
Cover Story
annual
consumers
The report notes situation
that much of the health industry
has accepted
many
need
drive
that reform is here to stay – and forward-looking executives are
initial
making decisions based on a post-ACA landscape that has altered
based
set
begin
drive
facing the U.S. health sector this year.
research
investors
term
personalized
open
stream
business.
phase
profile
The sophisticated
platforms
on
the
market,
like those provided
providing
by Life Technologies, are helping to drive the screening cost
way down, from about $150 per test to just $12. As clinical
laboratories are struggling for reimbursement dollars from the
healthcare system, these molecular solutions are affording labs the
opportunity to offer more of these tests while remaining profitable.
moving
PGx will prove to be the next big win in personalized medicine
-- for patients and biotech.
benefits
company
provides
life
markets
the provision of insurance and the delivery of care.
According to HRI, 10 issues stand out as the top focus for the
make
health industry in the year ahead:
• Price transparency is growing as purchasers – consumers and
employers – are demanding and receiving more information
premium
February
on cost and quality
Charles M. Baum, M.D., Ph.D.
• Employers are exploring new health insurance options through
President & CEO, Mirati
private exchanges
diagnostic
Therapeutics
• New regulation aims to eliminate
counterfeit medications in
maintain
There
is
a
significant
the drug supply chain
transformation underway in the
• States are turning to managed care to help contain Medicaid
field of oncology, not just in terms
long-term care costs
of our understanding of the biology
• All healthcare companies need to rethink their roles and
of the disease, but also how we are
significant
business models in the new health economy
conducting clinical trials. A trend
•
Healthcare companies will need to change their rules on
moving
we will see in clinical development
innovation — embrace “fail fast” approaches
in 2014 is the selection of patient populations based on defined
• Social, mobile, analytics, and cloud technologies are driving
abnormalities that make their tumors highly responsive to
information
new health industry
business models
nges genetic good
drugs that potently inhibit
those
genetic
alterations.
This
“precision
available
• Corporate venture capital is picking up the slack as traditional
sector
medicine” approach, like we are pursuing at Mirati, started when I
venture funding slows for pharmaceutical start-ups
was working at Pfizer on the development of Xalkori, one of the first
helpjob market
• Technology is redefining the healthcare
drugs approved with a companion
genetic diagnostic, and is now
sharing
• Drugmakers must rethink their clinical trial research methods,
becoming main stream. For example, a coalition of government
non
embracing alternative approaches
pharmaceutical
agencies, pharmaceutical companies, and a non-government
defined
seeing
tailored
organization have launched the “Master Protocol” study, a phase
II and phase III trial to evaluate multiple drugs, assigning patients
“A trend we will see in clinic al development
to therapy based on their specific tumor genetic profile.
in 2014 is the selection of patient
The benefits of the precision medicine approach are multiple:
those
populations based on defined
genetic
targeting specific patient populations with distinct genetic profiles
is much more efficient, allows for smaller studies involving only
abnormalities that make their tumors
150-200 patients, and provides a definitive answer much sooner
highly responsive to drugs that potently
as to whether or not the drug works. Most importantly, this products
inhibit those genetic alterations.”
approach allows for a treatment that is tailored to each individual
patient, resulting in a greater benefit and generally fewer side
— CHARLES M. BAUM, M.D., Ph.D.
ways
pricing
effects for
each patient. This is a profound step forward in the
oncology space, where in the past patients were subjected to drugs
price
largest
with considerable
toxicity without much predictability of response.
Michael Brown
still
2014
market
partners
large
effects
best
think
become
even
ideas
start
outcomes
field
many
ether
ahead
therapy
technologies
nds
quality
se
real
energy
funding
esearch
office
come
capital
clinical
products
use
find
part
rest
government
continue
allows
given
open
precision
past
space
treat
impact
over
first
William Molloie
Partner, PricewaterhouseCoopers LLP
Implementation of the Affordable
Care Act (ACA) is only one of the factors
forcing a rapid reshaping of the $2.8
trillion U.S. healthcare industry in 2014
according to PwC’s Health Research
Institute (HRI). In its annual report on
the Top Health Industry Issues for 2014,
PwC’s HRI identifies the top 10 issues
pipeline
see
issues
take
now
many
business
time
one
answer
energy
greater
close
stage
trend
hope
world
change
costs
IPO care
making
top remain
specific
resources
life
easy
Partner, Stradling Yocca Carlson &
Rauth
The IPO window flew wide open for life
science companies in 2013, allowing
San Diego life science companies to tap
public markets in a meaningful way for
the first time in years. Seven San Diego
companies went public in 2013 year –
all of them in the life sciences sector.
That’s up from one life science IPO for San Diego companies in
2012. The amounts raised in San Diego life science IPOs in 2013
7
patients
more
successful
robust
medical
deal
including
underway
using
Cover Story
close
system
healthcare
low
required
identify
event
high
jobs
data
little
example
sequence
company
provides
begin
totaled approximately $465 million, with Tandem Diabetes raise of
$138 million being the largest.
Many San Diego companies have taken steps to go public in
“thepersonalized
future is clearly in biotech and
annual
planning
2014, including Biocept, Celladon, Vital Therapies, and Auspex,
drive
biologics
with
regard
to
big
pharma
R&D”
all of which filed S-1s with the SEC in 2013. Also, with the JOBS
stream
— JOE PANETTA
Act’s allowance of confidential
statements, there may
phase registration profile
research
be several more San Diego life science company IPOs already
consumers
providing
many
situation
underway not yet known to the public.
The degree to which the public market window for this sector
initial
Joe Panetta
will remain open in 2014 depends largely on the performance of
President and CEO, Biocom
these newly public companies. In San Diego, life science firms
make
After years of testing the mood at JP
that went public in 2013 posted mixed results. Shares of four of
moving
Morgan
- was last year good, was last
the seven companies, Tandem Diabetes, Fate Therapeutics, Ambit
year bad, will this year be good or bad,
Biosciences and Receptos are trading above their initial offering
premium
February
will the IPO window stay open or will it
price. Shares of three companies are trading
below their initial
close – my take away this time was that
offering price.
we’re moving toward greater stability
diagnostic
Shawn Pynes
in the healthcare markets, and that’s a
maintain
Director of Employee Benefits, Barney
positive thing. Healthcare as an overall
& Barney
market was up 60% last year.
Starting January 1, 2014, the major
So, my first takeaway on the future from JP Morgan was, if
portions of the Affordable Care Act (ACA)
Obamacare is so bad wouldn’t the opposite be happening? So
went into effect. Now, businesses with
setting aside health insurance politics, pharma and healthcare
significant
50 or more full-time employees need to
providers are realizing is that we’ll have more insured individuals
moving
start executing a strategy to address the
under much more comprehensive requirements for healthcare
unprecedented operational and financial
plans, with pre-existing conditions included. Add to that the drive
challenges posed by the new law.
to bring costs down information
for providers and the impact of personalized
good
nges
To get out
in front of the changes and stay afloat in the competitive
medicine
–
diagnostics,
digital health products, scanning
available
life science industry, employers need to do the following:
equipment, etc.—the importance of these sectors comes into playsector
• Model the anticipated health care costs to understand the
as well.
help
financial hit you may face.
Calculating all of the costs,
sharing
My second takeaway was that the future is clearly in biotech
including the less obvious ones, is critical to having a
and biologics with regard to big pharma R&D. In fact, one point
non
comprehensive understanding of the financial implications.
pharmaceutical
that made an impression on me was that this year for the first
defined
• Determine the best approach
to providing health benefits
tailored
time, more than half of the products in development by big pharmaseeing
based on your expense structure and needs. Will your
will be biologics. We are already experiencing the benefits of this
organization “Pay” or “Play” beginning in 2015? Life
movement in San Diego, with acquisitions and partnerships by
Science employers need to understand the impact their
GSK, AstraZeneca and Cubist resultingthose
in the establishment of
strategy could take on attracting and retaining employees.
their continued presence here as a result. As for the question of
• Decide whether a defined contribution plan is the best
whether the IPO window will remain open or will close, that is no
way to proceed, including whether to participate in an
longer a matter of whether biotech is “in favor”. For the foreseeable
insurance exchange. This method re-engages employees in products
future it is because the need will be there.
the economics of health care by encouraging them to shop
for benefits just like any other product.
The ACA
represents the most sweeping changes to benefits
ways
pricing
since the passage of Medicare. Preparing for the big challenges
ahead will set you apart from competition and ensureprice
long-term
largest
still
sustainability.
working
benefits
right
critical
investors
term
big
open
based
set
drive
need
life
markets
2014
market
partners
large
effects
best
think
become
even
ideas
start
outcomes
field
many
ether
passion
window
health
trying
saw
ahead
therapy
technologies
nds
quality
se
real
energy
funding
research
come
capital
clinical
rest
office
products
use
find
8
part
government
continue
allows
given
open
impact
over
first
precision
treat
pipeline
see
issues
past
space
take
now
many
business
time
one
answer
energy
greater
close
stage
trend
hope
world
change
costs
IPO care
making
top remain
life
specialabout is
what’s
specific
resources
sense of san diego
easy
community
the
“BioMed Realty is a trusted partner to Regulus - their
entrepreneurial spirit and focus on supporting
the life science industry are key drivers of growth
to us and the San Diego community.”
— Kleanthis G. Xanthopoulos, Ph. D.
President & Chief Executive Officer, Regulus Therapeutics
discover true
partnership
For more information contact Tracy Murphy at 858 207 5931
biomedrealty.com
@biomedrealty
Public
Policy
By Jimmy Jackson,
Vice President of Public Policy, Biocom
New Year Brings New Policy Challenges for Biocom
Looking back, 2013 was a year of great change and
accomplishment for the Biocom public policy team. First, we
opened a full time Washington D.C. office. Within 11 months, our
lobbyist helped develop federal legislation that gave biorenewables
companies access to funding through the Biorefinery Assistance
Program. We also coordinated a letter, signed by 30 regional
life science associations, which made the sequestration of FDA
funding more relevant to an overwhelming majority of Congress
and their constituents.
On the state level, Biocom was a key player in helping Governor
Jerry Brown pass his economic development proposal. The
legislation included a state sales tax exemption for equipment
used in life science manufacturing, as well as R&D, one of the
only industries to get an exemption on R&D equipment. Biocom
also stopped all state legislation categorized as “priority oppose.”
Many of you were able to meet Governor Brown in person as he
joined us at the 2013 Biocom Annual Dinner in November.
In the final days of 2013, the Biocom board of directors
voted unanimously (among those casting a vote) to endorse
Councilmember Kevin Faulconer’s candidacy for Mayor of the City
of San Diego. Mr. Faulconer has been a great friend and advocate
for the life science industry in his time on the city council.
The life science industry spends most of its time looking
forward, not back. This year, Biocom, with report partner PWC, will
once again distribute its survey on the relationship between the
industry and the FDA. We hope you will take the time to complete
it so we have the highest quality data to take to the agency and
policymakers as they begin looking at what worked in the user fee
authorizations of 2012 and what needs to be addressed in the next
round of user fee negotiations.
This year will also carry many challenges. As an election year,
most observers do not expect a great deal of substantive new
policy work to come out of Washington D.C. But as budget writers
continue to look for sources of revenue to pay for federal programs,
the life science industry is always at risk.
The Affordable Care Act will continue to roll out, likely with
both opportunities and obstacles for Biocom member companies.
The FDA will also continue to implement the Food and Drug
Administration Safety and Innovation Act of 2012 (FDASIA),
and continue to issue new guidances. Unfortunately, there are
those who are working to erode intellectual property protections
for innovators, even after the passage of the America Invents Act
in 2011. Your Biocom Washington D.C. lobbyist will continue to
10
engage on these and many other issues.
On the state level, the day-to-day implementation of the
Affordable Care Act will be a key issue, especially as so many states
look to California as a leader in managed care implementation.
Coverage and access to appropriate therapeutic options will be
paramount. Several local governments around the country have
enacted, or are considering, prescription drug and combination
product take-back programs, mandating that the pharmaceutical/
biotherapeutic industry bear the entire cost for these programs.
Preventing a labyrinth of different programs will be a priority.
At the local level, Biocom is working with many other
stakeholders to repeal the massive increase in City of San Diego
affordable housing fees charged to developers and landlords, as
well as engaging with local regulatory agencies as their proposals
affect the industry.
You can keep up with these subjects and all other policy issues
being worked on by Biocom by going to the revamped Biocom
policy section at www.Biocom.org/public_policy.
Jimmy Jackson is the Vice President
of Public Policy for Biocom. He oversees
government affairs and public policy for the
organization.
MEMBERS IN ACTION
BREAKFAST MEETING: Joe Panetta of
Biocom, Ken Baldwin of Ferguson Pape
Baldwin Architects and Supervisor
Dave Roberts; Michele Yelmene of
Pharmalink Consulting, EJ Brandreth of
Ajinomoto Althea and John F. Wood of
Arena Pharmaceuticals, Inc.
BREAKFAST MEETING
11
MEMBERS IN ACTION
ANNUAL CELEBRATION OF LIFE DINNER
Photos : JT MacMillan Photography
ANNUAL CELEBRATION OF LIFE DINNER. Clockwise from left: California Governor Jerry Brown; Heidi Chokeir of Canale Communications, Joe Panetta of Biocom and
Cammy Duong of Canale Communications; Kareem Dossa of VWR toasting to the success of the life sciences industry in 2013; Keynote Speaker Jill Bolte
Taylor; The Biocom Team: Michelle Wright, Katelyn Doyle, Jennifer Landress, Ashleigh Berry, Jane Zeyak and Heather Ramsay; Chuck Cashion, Paulina Chatfield
and Don Ripley of Conatus Pharmaceuticals.
12
EVENTS
By Ashleigh Berry,
Associate Manager of Events, Biocom
Ten Reasons You Should Attend an Event
It is easy to become swamped by day-to-day tasks, making it
difficult to escape from the office for a few hours, let alone an
entire day, for a business event or conference. Still, the take-home
can be tremendously valuable. Events and conferences can be your
resource for success, both personally and professionally. Here are
my top 10 reasons you should attend some of Biocom’s events and
conferences this year.
1. Networking: Social media outlets, while extremely beneficial
in this era of online communication, make it way too easy to
neglect actual face time. Attending a business event encourages
you to interact with like-minded individuals within the industry and
get talking. Biocom events help individuals create an extensive
network of fellow professionals in the life science industry. To
ensure valuable networking time, Biocom hosts quarterly breakfast
meetings that offer a dedicated hour of networking before the
panel discussion.
2. Learning: This industry is constantly growing and changing.
Attending business events helps keep you up-to-date on the latest
trends. Not only does learning about the industry enhance your
skill set, it also allows you stay in contact with others. Biocom
advances your knowledge by offering programs on the unique
challenges faced by life science companies.
3. Events can be fun!: Not every event has to be all work and
no play. Corporate events can be fun as well. Evening events and
full-day conferences typically end with a reception, which includes
food and drinks. Biocom members receive complimentary drink
tickets at these networking forums. This atmosphere can make
networking much more approachable. Furthermore, Biocom often
includes themes and added elements at our casual receptions to
excite your interest. Biocom is currently in our 4th year of hosting
an evening networking gala that includes whisky, tequila and wine
tastings, along with a professional cigar roller. The cigar is yours
to keep.
4. Hear from Industry Experts: Event attendees not only have the
opportunity to learn from industry experts, but can also interact
with them directly following their panels. Sitting in on the panel
sessions also gives you the opportunity to ask these industry
leaders questions about the panel topic. Every panel has a Q&A
portion, during which we open the floor to all guests. Questions
from the audience are invaluable, as they provide opportunities to
learn from your peers.
5. Find inspiration: Don’t get caught up in the same day-today work routine and lose focus. Networking and interacting with
others is a great way to bounce fresh ideas off each other and
regain that inspiration. You will leave with handouts and notes,
new resources and hopefully new perspectives.
6. Increase your visibility: Attending an event increases visibility
for both you and your company. Each time you share your business
card, you are creating new contacts that can be valuable for both
your personal and professional growth.
7. Discover new opportunities: Attending business events is a
great way to market yourself if you are trying to get hired within
the industry or looking to attract top talent on behalf of your
organization. Events are a wonderful tool to connect and evaluate
new opportunities.
8. Stay competitive: More than likely, your competitors are
attending the same events you are. Speak with these companies.
Observe how other attendees are responding to them. This helps
you observe firsthand what their strengths and weaknesses are and
allows you to gain a competitive edge.
9. Experience new venues: Attending an event is a fun way to
discover new restaurants and venues in your city. Allow Biocom to
introduce you to the newest locations and indulge in gourmet food
and beverages. Typically, event planners have access to unique
locations that you might not be able to experience otherwise. Last
summer, Biocom hosted an evening reception at the membersonly University Club that overlooks downtown San Diego. Biocom
has also hosted multiple evening receptions at the Evans Garage,
an antique and classic car museum that is closed to the general
public. This year, you can expect more exciting receptions at new
or specialized venues.
10. High-caliber speakers: Attending larger conferences and
events gives you an opportunity to hear from celebrities and highcaliber community speakers you might not hear otherwise. In the
past, Biocom has hosted Governor Jerry Brown, as well as famous
TED speakers Jill Bolte-Taylor, Montel Williams, John Crowley and
Bob Saget, to name a few.
With numerous events and industry conferences to choose from,
it can be overwhelming and time-consuming to attend them all.
It is not necessary to attend every event that comes your way, but
attending several throughout the year can help you immensely on
your path to professional growth.
Ashleigh is the Associate Manager of Events
for Biocom and is in charge of organizing and
marketing Biocom events.
13
Premier Supplier in the
Purchasing Group
Since 2002,
Prudential Cleanroom Services
and Prudential Overall Supply
continues to provide BIOCOM
Members reusable textile products
and services for rental, lease and
direct purchase programs.
ISO 9001:2008 CERTIFIED
TRUSTED BY LEADERS
A DIVISION OF PRUDENTIAL OVERALL SUPPLY
WWW.PRUDENTIALUNIFORMS.COM
800-767-5536
PRU D EN T I A L I S
DEDI CATED TO SU STA IN A BIL IT Y
Premier Supplier in the
Purchasing Group
PRUDENTIAL IS...
THE RIGHT
CHOICE
CAREER & CASUAL
FACILITY PRODUCTS
PROTECTIVE APPAREL
MEDICAL APPAREL
CULINARY APPAREL
NAPKINS
TOWELS
MOPS & BUCKETS
RESTROOM PRODUCTS
CLEANROOM
MATS
800-767-5536
WWW.PRUDENTIALUNIFORMS.COM
Guest
By Mandy Jackson,
West Coast Editor, SCRIP Intelligence
San Diego Public Companies to Watch in 2014
Legacy firms and recent IPOs face important milestones
San Diego’s biotechnology cluster will be a newsworthy group
in 2014, with several companies on track to achieve research and
regulatory milestones for drug candidates in their pipelines.
While the region lost some long-time biotech industry members
to acquisitive companies in 2013, stock market gains and initial
public offerings (IPOs) gave other businesses the resources they
needed to grow.
Cubist Pharmaceuticals bought the antibiotic developers Trius
Therapeutics and Optimer Pharmaceuticals for more than $1.2
billion plus future milestone fees. But while decision-making
responsibilities for Trius and Optimer have shifted from San Diego
to Lexington, Mass., many local biotech firms showed their staying
power in 2013.
Antisense drug developer Isis Pharmaceuticals strengthened
its presence in Carlsbad with a 268 percent increase in its
stock price between January and December, bringing its market
capitalization to $5.6 billion as of January 21. The company had
more than $625 million in cash at the end of 2013 to support its
development pipeline, which includes five drug candidates that
could be submitted for U.S. Food and Drug Administration (FDA)
approval by 2018.
Isis’s partner Genzyme launched the homozygous familial
cholesterolemia drug Kynamro (mipomersen sodium) in 2013. Isis
also reported positive data from 10 clinical trials for five different
antisense drugs, initiated one new Phase III and five new Phase II
trials and added four new drug candidates to its pipeline.
“Those successes set the stage for even more success in 2014
and more to follow,” Isis chairman and CEO Stanley Crooke said
during his presentation on January 13 at the 32nd Annual JP
Morgan Healthcare Conference in San Francisco.
The high-profile JP Morgan conference has become the annual
kickoff event for the life science industry. This year’s conference
was the first time Helen Torley spoke at a major investor event as
the new president and CEO of Halozyme Therapeutics, another
mainstay San Diego biotech company.
Dr. Torley said 2014 will mark a transformation for Halozyme
as it shifts from enabling subcutaneous versions of intravenous
medicines on behalf of its partners to producing novel therapeutics
for the company’s own portfolio.
“No longer the royalty platform story, we are transforming into
16
a products company as well with a diversified pipeline,” she said
on January 16.
Halozyme will announce clinical trial enrollment progress for the
anti-cancer agent PEGPH20 during the second half of 2014. The
company also plans to report top-line data during the first quarter
for Hylenex, which treats type 1 diabetes, and from a Phase II
cellulite study with HTI-501. In terms of partnered programs, the
FDA should make an approval decision for Baxter’s HyQvia by mid2014. Also, a European Medicines Agency (EMA) committee is
expected to make a recommendation for Roche’s subcutaneous
MabThera this year.
Orexigen Therapeutics has marketing applications pending in
the U.S. and Europe. The San Diego-based company should have
an FDA decision by June 20, and an EMA recommendation by the
fourth quarter of 2014, for its obesity drug Contrave (naltrexone
SR/bupropion SR).
Orexigen’s prescription weight loss therapeutic will compete with
Belviq (lorcaserin) from San Diego-based Arena Pharmaceuticals.
Arena’s partner Eisai launched Belviq in the U.S. on June 11 and
Vivus of Mountain View, California began selling its obesity drug
Qsymia (phentermine and topiramate) in September 2012.
The competition between the obesity drug developers garnered
a lot of attention in 2013, and that’s not likely to change in 2014,
as Orexigen nears U.S. and European approvals.
But the biggest news in biotech last year – in San Diego and
elsewhere – was the open window for IPOs, which doesn’t look like
it will close anytime soon.
Six San Diego-based companies were among the 38 drug
developers that completed an IPO in the U.S. in 2013: Receptos,
Ambit Biosciences, Conatus Pharmaceuticals, Sophiris Bio, Evoke
Pharma and Fate Therapeutics.
Ambit will start a Phase III clinical trial for the acute myeloid
leukemia drug quizartinib in early 2014. Sophiris will complete
patient enrollment for the first Phase III trial for PRX032, to treat
benign prostatic hyperplasia (BPH), during the second half of the
year.
Evoke also has plans for a Phase III clinical trial to test EVK-001
(intranasal metoclopramide) to manage diabetic gastroparesis. An
earlier-stage company, Fate expects to restart a Phase II trial in
adult hematologic malignancies in the first half of 2014 for its
Guest
hematopoietic stem cell therapy ProHema.
Conatus intends to announce Phase IIb clinical trial results for
emricasan, to treat acute-on-chronic liver failure (ACLF), in the
first half of 2014. The company will also initiate a Phase II trial
for nonalcoholic steatohepatitis (NASH) and Phase IIb studies
for chronic liver failure (CLF) and hepatitis C virus – post-liver
transplant (HCV-POLT).
Finally, Receptos recently began the Phase III portion of the
Phase II/III RADIANCE clinical trial for RPC1063, which treats
relapsing multiple sclerosis (RMS). The company expects to start
a second Phase III RMS trial after it reports Phase II RADIANCE
data in mid-2014.
Annual Open House
And Purchasing Group
Supplier Showcase
Wednesday, July 23rd
4-7pm
Biocom Courtyard
Mandy Jackson writes about small and midsized biotech companies for the biopharma
news website Scrip Intelligence.
www.biocom.org
Make Your Mark
in
BiotechnologY
Professional Science Master’s
The Professional Science Masters in Biotechnology is the premier
degree in San Diego. This innovative degree incorporates advanced
biotechnology coursework and laboratory training with MBA-level
business courses. The part-time evening program accommodates the
needs of working professionals. Our graduates are well-prepared for
successful careers and advancement in the life science industry.
For more information contact us at
www.csusm.edu/el/degreeprograms/psmlifelines/index.html
HURRY!
Fall 2014 Start
ApplY
TodAY
Science
Festival
By Sara Pagano,
Managing Director, SD Festival of Science & Engineering
BE THERE
San Diego Festival of Science & Engineering, March 22
More than 25,000 San Diegans are expected to attend the San
Diego Festival of Science & Engineering (SDFSE) on Saturday,
March 22 at PETCO Park. Join us there for more than 100 different
hands-on activities that will excite your mind about science,
technology, engineering and mathematics (STEM).
This event is geared towards children kindergarten through
college but is open to anyone who wants to learn about STEM
and how this industry is thriving in our own backyards. Come with
your family and friends and open them up to this world and the
dedication that drives our industry. The innovations of the future
are being created right beside us every day. All it takes is one spark
to ignite a child’s passion.
Some of those future innovators have already showed their stuff
by winning a Bright Idea Society award. This program encourages
schools to submit ideas for STEM-related, project-based learning.
Winners are chosen from three categories: elementary, middle and
high school. Each school receives a $500 stipend to bring their
project to fruition, booth space at the Festival to present their
activity to the community and transportation to and from the event.
This annual education program is sponsored by the Kimmich
Foundation, and transportation this year is being provided by the
San Diego Financial Literacy Center.
SDFSE is free and open to the public thanks to our many
wonderful sponsors. Some of this year’s top contributors include:
ABC10 /10News & Azteca San Diego 15, Biocom, Cox Media,
Jammin’ Z90 and Magic 92.5, Life Technologies, San Diego
Padres, Time Warner Cable and ViaSat, Inc.
In addition, we are very excited to have three educational
partners on board: The Reuben H. Fleet Science Center, The San
Diego County Office of Education and University of California, San
Diego. Their support, along with a host of additional sponsors,
helps make this a free community event.
If you can’t make it to PETCO on the 22nd, not to worry, there
are still plenty of opportunities to participate in the Festival with
its week of activities throughout the county.
• Visit Taylor Guitars, where guests will tour the facility and
learn the steps of guitar construction from wood selection to final
assembly.
• Check out the Escondido Police Department, which will expose
students to the Crime Lab and Traffic Division and how they use
math and physics to complete investigations. They will showcase
equipment to gather data and conduct experiments. Officers and
18
SAVE T
HE
DATE
MARCH 201
4
MA RC H
15TH-21ST
Science, Technology, Engineerin
g & Math
STEM Events
Throughout San Diego County
www.sdsc
p
MA RC H
22ND
i
EXPO DAY at
PETCO Park
iencefestiv
al.com
E
FRETIONAL
CA
EDU
e
FUN
laboratory technicians will explain how scientific principles are
used daily to solve crimes and determine how traffic collisions
occurred.
• Have little ones? Visit The New Children’s Museum (NCM),
where they are experimenting with food’s many possibilities in
their latest exhibition, Feast: The Art of Playing With Your Food.
You’ll be invited to play inside “Mold” - the museum’s one-of-akind building block environment made entirely of fungi. Children
will have the opportunity to explore different mushroom species
by creating mushroom stamp prints in a special workshop in the
NCM Art Studio.
For a full listing of events, to see what’s happening in your part
of town, and more information on Festival Day, please visit www.
sdsciencefestival.com. We look forward to seeing you and your
family during Festival Week.
Sara Pagano is the Managing Director of the
San Diego Festival of Science & Engineering
We have advanced the art
of HIPAA, FDA & Unified
Compliance to a Science
Biocom
Institute
By Liisa Bozinovic,
Executive Director, Biocom Institute
Life Science Summer Institute Celebrates 10th
Anniversary of Developing a Workforce Pipeline
The San Diego Workforce Partnership, in collaboration with
Biocom and the Southern California Biotechnology Center at
Miramar College, created the Life Sciences Summer Institute
(LSSI) to strengthen science and math education and prepare
people for careers in the life sciences.
LSSI programs target two populations, high school students and
high school teachers. The goal is to encourage youth to explore
careers in science, technology, engineering and math (STEM).
LSSI was originally piloted with a Department of Labor grant.
Today, it is fully supported and funded by the biotech industry.
This year, LSSI celebrates its 10-year anniversary.
LSSI provides high school students with summer internships,
including a one-week, pre-internship “boot camp” to prepare them
for hands-on research experience. Since 2005, the program has
trained and placed more than 366 students in summer research
internships, working alongside Nobel Prize-winning scientists,
participating in scientific talks and conducting hands-on research.
Students earn college credit for their boot camp course,
receive college prep units from the University of California San
Diego Extension and create a scientific poster of their work. The
program has expanded to run two concurrent boot camp sessions
at Grossmont College and Miramar College and maintains strong
partnerships with both the Salk Institute and the Scripps Research
Institute. Students from all areas of San Diego apply to be part
of this highly competitive program. LSSI receives more than 300
applications per year for only 35 to 40 positions.
Jake Maskiewicz credits LSSI for his major successes. During
the summer of 2010, Maskiewicz interned in a computational
biology lab at the Salk Institute and has remained there ever since.
Lesly Basave, a student from a small charter school, faced
many challenges including working late nights with her parents
cleaning office buildings. Science was never a career option for
her. However, after interning at The Scripps Research Institute
she was offered part-time employment and went on to pursue a
biology major. LSSI provides youth with classroom and experiential
opportunities that empower them to broaden their career horizons.
In the 12-day professional development program, science
teachers receive training through the Amgen Biotech Experience
(ABE) curriculum and exposure to companies, such as Conatus,
Genentech, Illumina, Life Technologies, Pfizer, Pharmatek, Pfenex
and Sapphire Energy. By the end of the course, teachers have
the skills, equipment, and supplies necessary to implement the
20
curriculum in their classroom. Teachers also receive first-hand
knowledge about the job market, as well as the hard and soft skills
needed to be successful in the biotech workplace.
The program has trained more than 180 science teachers across
San Diego, Riverside and Orange Counties, impacting more than
37,000 students and sparking student excitement at scientific
discovery.
The program has extended its services to Riverside County,
providing materials and lab equipment for teachers. Through
Miramar College’s Biotechnology program, teachers can articulate
their high school biotechnology courses. More than 780 students
have passed the credit-by-exam process, eliminating duplication of
learning in post-secondary education.
Today, LSSI has expanded its training to include a two-week
bridge program. The Introductory Life Sciences Experience (ILSE)
was first piloted in 2009 to provide students experiencing economic
and social barriers with direct exposure to the life sciences industry
through hands-on laboratory training, interactions with scientists
and visits to biotechnology sites across San Diego.
The program has trained more than 70 students and has ignited
their interest in STEM-related opportunities. Students taking part
in these programs have received scholarships, have been accepted
into Ivy League universities and have become gainfully employed
in science-related fields. LSSI has been a vehicle to help decrease
the region’s gap in STEM employment.
The program’s application period is currently open and
information can be viewed at www.matsc.org. Become part of
the LSSI team by hosting teachers, hiring an intern or providing
student sponsorships.
For more information, contact Erika Aranguré, San Diego
Workforce Partnership, at [email protected]. This is your
opportunity to help promote STEM education by supporting a wellestablished program with 10 years of proven success.
Liisa Bozinovic is the Executive Director of
the Biocom Institute and also heads Biocom’s
HR initiative.
ALWAYS HELPFUL.
ALWAYS RELIABLE.
Every company requires help along
the path to success. Finding service
providers you can count on can be
time-consuming and difficult. Let us
help you by connecting your needs
with the services of a trusted fellow
Biocom member.
www.Biocomconcierge.org
Purchasing
Group
By Rick Fultz,
Managing Director, Biocom Purchasing Group
Our 2014 New Year’s Resolutions
As we close the chapter on one of our most successful years
to date, we’d like to take this opportunity to extend our heartfelt
gratitude to our members for their participation in our contracts.
This participation has allowed us to attract industry-leading
suppliers to our RFPs, secure stronger price concessions and bring
more robust contract offerings. Your willingness to be a team player
has led to unparalleled savings and services for all our members.
With last year’s appointment of our quality control specialist, we
were finally able to deliver on the increased contract compliance and
quality control systems that our members have requested. Together
with our expanding member base of qualified professionals, we
completed our first successful circuit of advisory committees for
all six contract areas.
We have honed in on five major goals for 2014, and with your
assistance, we expect to knock these out of the park.
1. Save You Even More Time and Money
The Biocom Purchasing Group saved members more than $60
million in 2013, up from $48 million in 2012. One contributor to
this increase was our partnership with Barney & Barney’s Beyond
Benefits program: the first-of-its-kind health care trust that helped
our members leverage the positive health risk of the life science
industry. Since its inception, more than 88 members have joined,
saving more than $2.3 million.
In 2014, we’re setting the aggressive goal of saving Biocom
members more than $75 million. This benchmark is inspired by
our members and reflects the commitment we have to you.
2. Add More of the Services You Need
It is hard to believe that, with more than 40 suppliers in
our savings portfolio, we still have not accounted for all your
procurement needs. With last year’s introduction of new member
surveys, formal feedback systems and member retention meetings,
however, we were able to identify three contract areas for which we
plan to conduct RFPs in 2014-2015. Be on the lookout for RFP
committee invitations for mobile communications, e-procurement
tools and domestic airlines. As always, please do not hesitate to
contact us with suggestions at [email protected].
3. Enhance Our Communication Channels
Another takeaway from our recurring advisory committee
meetings is the concept of hosting bi-annual conference calls/
webinars to discuss current suppliers, prospective contract areas
and the industry’s competitive landscape. The Biocom Purchasing
22
Group always operates in the best interest of our membership.
However, the possibilities are endless when we can collaborate
with more than 600 member companies to address key focus areas
and create plans for the future. Our first call is scheduled for May
2014, and we look forward to hearing from you.
4. Incorporate More Value-Added Benefits
Last year’s introduction of our Supplier Event Series was a
huge success, consolidating events for our members and forging
stronger, industry-specific partnerships. We will continue to press
on our suppliers to offer additional value-added services at low or
no cost to you. Veolia, our endorsed waste management supplier,
is starting the trend this summer with their complimentary RCRA
& DOT 2-day training and certification program. For all Biocom
members who work at or oversee hazardous waste operations, we
strongly encourage you to take advantage of these free resources
and industry-mandated certifications.
5. Expand the Biocom Travel Network
The Biocom Travel Network is a full-service program, offering
members exclusive access to competitive, high-volume discounts
to destination hotels, travel booking tools and air and ground
transportation programs, regardless of their company size or travel
frequency. We also have a heavily discounted contract lined up with
Concur, the travel and expense management supplier of choice
with many member companies, offering integrated solutions for
travel bookings and policy and regulatory compliance. In 2014,
we plan to aggressively pursue additional hotel discounts in
Boston, New York City and Washington, D.C. Our goal is to create
a comprehensive travel program that strengthens business for our
members in San Diego and beyond.
We thank you all for your continued support and look forward to
serving your procurement needs for many years to come.
Rick oversees membership and sponsorship
efforts, business development opportunities,
and the Biocom Purchasing Group.
Silent
Auction
San Diego craft
brew tastings
Golf Pro
Trick Shot
Show
Hole
in One
Contests
rity
a
h
C
m
Bioco
m
a
e
n
n
t
r
u
o
T
f
G ol
21, 2014 The Santaluz Club
l
i
r
p
A
day
n
o
M
Gourmet
dinner
BENEFITING:
Space is limited and registration
is filling up fast! Sign up today to
secure your place.
www.Biocom.org
And much
much
more........
SPONSORED BY:
PREMIUM MEMBER SPOTLIGHTS
PREMIUM MEMBERS
AbbVie*
Ajinomoto Althea
Alexandria Real Estate Equities
Arena Pharmaceuticals
Bayer Healthcare
Biomed Realty Trust
Bioserv Corporation
Biospace
BP Biofuels
Cadence Pharmaceuticals*
California Manufacturing Technology
Consulting
Canale Communications
Celgene
COI Pharmaceuticals
Conatus Pharmaceuticals
Cooley
County of San Bernardino Economic
Development Agency
Deloitte
DLA Piper
Eli Lilly
Ernst & Young
Ferring Research Institute
Fisher Scientific
Foley & Lardner
GE Healthcare Life Sciences
Genoptix
Hologic
Janssen Research & Development
Jones Day
KPBS
Latham & Watkins
Life Technologies
Mentus
Merck Research Laboratories of San Diego
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo
NuVasive
Patheon
Pfizer
Praxair*
PwC
VWR International
Wilson Sonsini Goodrich & Rosati
* New Members from October 2013 to January 2014
24
www.fishersci.com
Name: Bill Yang
Job title: Vice President Sales, West Region
Favorite movie: She Wore a Yellow Ribbon
Favorite book: The Complete Far Side, Volume I and II”, Gary Larson
Favorite quote: “Be civil to all; sociable to many; familiar with few;
friend to one; enemy to none’. Benjamin Franklin
Favorite TV show: Big Bang Theory
Favorite restaurant or meal: Stella Alpina Osteria (Italian) in the Bay
Area
Favorite city: Madrid
Favorite actor/actress: John Wayne/ Diane Keaton
Favorite thing to do on the weekends: Spending time with family and friends
What CD can we find in your car: Toby Keith “Unleashed”
Favorite hobby: Bicycling
Favorite website: www.facebook.com
First job: First non professional job: Paper route. First professional job: Sales representative at
American Scientific Products
Favorite part of your job: Building relationships with our customers, learning about their research
and contributing to their discoveries and successes.
If you could have another career, what would it be: Veterinarian
Why did you start working in your industry:A fascination with science at a young age. I remember
sitting on the floor, encyclopedias spread all around me and being amazed at everything that had
been discovered and all that was still left to be discovered.
www.gelifesciences.com
Name: David Sanborn
Job title: Sales Specialist
Favorite movie: The Good, The Bad and The Ugly
Favorite book: “1421”
Favorite quote: “Do not dwell in the past, do not dream of the future,
concentrate the mind on the present moment.” Buddha
Favorite TV show: Star Trek; The Next Generation
Favorite restaurant or meal: Saffron in Mission Hills
Favorite city: San Diego
Favorite actor/actress: Clint Eastwood
Favorite thing to do on the weekends: Events and outdoor activities with my family
What CD can we find in your car: John Butler Trio
Favorite hobby: Working in the yard
Favorite website: GE Life Sciences
Favorite spot in Southern California: Torrey Pines State Beach Park
First job: Research Scientist at Thomas Jefferson University
Favorite part of your job: Meeting and working with scientists in southern California
If you could have another career, what would it be: National Park Ranger
Why did you start working in your industry: Interest in human physiology
PREMIUM MEMBER SPOTLIGHTS
www.janssenlabs.com
Name: Kara Bortone, PhD
Job title: Head of Company Sourcing
Favorite movie: Amélie
Favorite book: One Thousand Splendid Suns by Khaled
Hosseini
Favorite quote: “Take your work seriously, but never
yourself” – Margot Fonteyn
Favorite TV show: 30 Rock
Favorite restaurant or meal: Fish tacos
Favorite city: Barcelona
Favorite actor/actress: Audrey Hepburn
Favorite thing to do on the weekends: Cook a big meal and enjoy it with friends and
family
What CD can we find in your car: London Calling – The Clash
Favorite hobby: Mountain biking
Favorite website: YouTube
Favorite spot in Southern California: Santa Monica
First job: Rollerblading Subway Sandwich Artist at the boardwalk
Favorite part of your job: Meeting entrepreneurs that are dedicated to pushing the
edge of what is possible
If you could have another career, what would it be: Architect
Why did you start working in your industry: I wanted to be at the interface of science
and business and be a part of delivering life changing solutions to patients.
www.wsgr.com
Name: Dan Koeppen
Job title: Partner
Favorite movie: Goodfellas, Something
Ventured, and Toy Story 2
Favorite book: “When Pride Still Mattered :
A Life Of Vince Lombardi” and “Howard B.
Wigglebottom Learns to Listen”
Favorite quote: “Never mistake activity for achievement” – John Wooden
Favorite TV show: The Wire, Sopranos, Sons of Anarchy, Breaking Bad, House of
Cards, and Jake & the Never Land Pirates
Favorite restaurant or meal: O’Sullivan Bros. Brewing Co. Tasting Room & Beer
Garden (coming in 2014)
Favorite city: San Diego
Favorite actor/actress: Ian Dale
Favorite thing to do on the weekends: Play basketball and spend time with my wife
and two kids.
What CD can we find in your car: Something from the 90’s like “Monster Ballads”
because that’s the last time I bought a CD.
Favorite hobby: Basketball, skiing, and watching the Green Bay Packers
Favorite website: www.espn.com and www.jsonline.com/sports
Favorite spot in Southern California: Sage Canyon Park
First job: Cedarburg (WI) Department of Public Works
Favorite part of your job: Being able to help entrepreneurs create valuable products
and services and have successful exits.
If you could have another career, what would it be: High school basketball coach and
history teacher.
Why did you start working in your industry: It was my desire to be able to have an
influence in building and growing companies that create novel products and
services that affect people’s lives.
BECOME A PREMIUM MEMBER TODAY
With our premium membership you get
increased visibility and added value to your
membership. We offer our premium members
maximum exposure opportunities and access to
exclusive events in the life science community.
To become a premium member contact:
Kira Jenkins, Director of Membership
[email protected] or 858.455.0300 x117
Company logo seen by 100,000 life science professionals.
Company news briefs and event announcements sent to over
360,000 people annually.
Additional discounts offered at key conferences
An employee featured in LifeLines Magazine
Direct access to 15,000 people through a targeted email blast.
And many more......
25
Board of Directors
BOARD OFFICERS AND EXECUTIVE COMMITTEE:
CHAIR: Magda Marquet, Ph.D., Ajinomoto Althea*
VICE CHAIR: Carin Canale-Theakston, Canale Communications*
CHAIR ELECT: Theodore Schroeder, Cadence Pharmaceuticals*
VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper*
VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young*
VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield*
VICE PRESIDENT – INDUSTRY: Daniel Burgess
CHAIR EMERITUS: David Webb, Ph.D.*
PRESIDENT & CEO: Joe Panetta, Biocom*
Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo
Remi Brouard, M.D., Sanofi R&D West Coast
Michael Brown, Stradling Yocca Carlson & Rauth
Terrance J. Bruggeman, BioTork, LLC
Timothy Caulfield
Daryl Dorcy, AbbVie
John M. Dunn
Geoffrey S. Eich, Amgen
Stephen Ferruolo, J.D., Ph.D., USD School of Law*
M. Wainwright Fishburn, Jr., Cooley LLP*
Don Fitzgerald, Genentech
Jack Florio, Brinson Patrick Securities
Gregory Frost
Alan Gold, BioMed Realty Trust
Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati
Terry Gregg, Dexcom
Jason Hannon, NuVasive
Richard Heyman, Ph.D., Seragon Pharmaceuticals
Jim Hinrichs, CareFusion
Elliot Hirshman, Ph.D., San Diego State University
Matthew Hudes, Deloitte LLP
Guy J. Iannuzzi, Mentus
David Kabakoff, Ph.D., Sofinnova Ventures
Steve Kaldor, Ph.D., Quanticel
Michael Kamdar, Cellana, Inc.
Katherine Kantardjieff, Ph.D., California State University San Marcos
Paul Laikind, Ph.D., ViaCyte
Kevin Larkin, TherOx
Jacob Levin, Ph.D., UC Irvine
James Levine
Jack Lief, Arena Pharmaceuticals, Inc.*
Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.*
William Molloie, PwC
Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.*
Brian O’Callaghan
Kenneth Polin, Jones Day
Trindl Reeves, Barney & Barney LLC*
Gregory Reyes, M.D., Ph.D., Celgene
Dan Ryan, Alexandria Real Estate Equities
Camille Saltman, MD Revolution
James Schaeffer, Ph.D., Merck Research Laboratories*
Christophe Schilling, Ph.D., Genomatica, Inc.*
Timothy Scott, Pharmatek Laboratories, Inc.*
Martin Seidel, Ph.D., Genomics Institute of the Novartis Research Foundation
Bhasker Shetty, Ph.D.,Pfizer La Jolla
Larry Stambaugh*
Mark Stevenson, Thermo Fisher Scientific *
Scott N. Wolfe, Latham & Watkins
Randall E. Woods, Sophiris Bio*
LIFE DIRECTOR:
Kennon W. Baldwin, Ferguson Pape Baldwin Architects*
David Hale, Hale BioPharma Ventures*
Tina Nova, Ph.D., Genoptix, Inc. A Novartis Company
Biocom Board Members-Ex-Officio:
Sandra Brown, Ph.D., UCSD
Mark Cafferty, San Diego Regional Economic Development Corporation
Constance Carroll, Ph.D., San Diego Community College District
Scott Lippman, MD, Moores Cancer Center, UCSD
Peter Preuss, The Preuss Foundation
Jerry Sanders, San Diego Regional Chamber of Commerce
*Executive Committee Member
Committee leadership
Capital Development Committee*
Carin Canale-Theakston, Canale Communications
David Kabakoff, Ph.D., Sofinnova Ventures
CRO Committee
Timothy Scott, Pharmatek Laboratories, Inc.
Environmental, Health and Safety Committee
Cliff Hanna
Dan Shiel, Pfizer La Jolla
Facilities Committee
Andy Darragh, Ferguson Pape Baldwin Architects
Brent D. Jacobs, Cushman & Wakefield
FDA Committee
Magda Marquet, Ph.D., Ajinomoto Althea
Michele Yelmene, Pharmalink Consulting
Intellectual Property and Patent Law Committee
Margaret Dunbar, Sanford-Burnham Medical Research Institute
Daniel Hart, Knobbe Martens Olson & Bear LLP
Legislative Committee
Richard Ledford
April Grant, Sunovion Pharmaceuticals
Medical Device Committee
Noel Gillespie, Procopio, Cory, Hargreaves& Savitch
Joleen Schultz, Rady School of Management, UCSD
mHealth Committee
Camille Saltman, MD Revolution
Public Policy Oversight Committee*
Larry Stambaugh
Paul Laikind, ViaCyte
Purchasing Board Committee*
Jack Lief, Arena Pharmaceuticals, Inc.
Scholarship Committee
Bente Hansen, BenteHansen and Associates
Biocom Institute Board Committee*
Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.
27
Biocom MEMBERSHIP
PREMIUM
Cadence Pharmaceuticals*
California Manufacturing
Technology Consulting
Canale Communications
Celgene
COI Pharmaceuticals
Conatus Pharmaceuticals
Cooley LLP
County of San Bernardino Economic
Development Agency
Deloitte
DLA Piper
Eli Lilly
Ernst & Young
Ferring Research Institute
Fisher Scientific
Foley & Lardner
GE Healthcare Life Sciences
Genoptix
Hologic
Janssen Research & Development
Jones Day
KPBS
Latham & Watkins
Life Technologies
Mentus
Merck Research Laboratories of
San Diego
Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo
NuVasive
Patheon
Pfizer
Praxair*
PwC
VWR International
Wilson Sonsini Goodrich & Rosati
Biotechnology
BioWa
Boehringer-Ingelheim
Curtana Pharmaceuticals
CalciMedica
CannaVest Corporation
CARBOGEN AMCIS
Cebix
Cell Applications
Celladon
Cellana
Cell Signaling Technology*
Center for Aquaculture Technologies
Cibus
Coda Therapeutics
Conju-Probe
Contract Biotics
CURx Pharmaceuticals*
Custopharm
Dart Neuroscience
Denovo Biomarkers
DSM Food Specialties
eFFECTOR Therapeutics
Electronic BioSciences
eMolecules
Epeius Biotechnologies
Equitech Bio
Fabrus
Fate Therapeutics
Formex
Genelux Corporation
Genentech
Genlantis
Genoa Pharmaceuticals
Genomatica
Genovo Corporation*
GenSignia
GlaxoSmithKline
Guangdong Consun Pharmaceutical
Company*
GWR Instruments
Halozyme Therapeutics
Harbor Therapeutics
Histogen
Huya Bioscience International
Illumina
Inception Sciences
Inhibrx
InnoPep
Innovative Cell Technologies
Inovio Pharmaceuticals
Integrated DNA Technologies
Intercept Pharmaceuticals
International Stem Cell
Intrepid Therapeutics
Intrinsic LifeSciences
Invetech
InvivoGen
IRBCo.
ISIS Pharmaceuticals
Jaleva Pharmaceuticals
J-Oil Mills
Kalyra Pharmaceuticals
Kyowa Hakko Kirin California
La Jolla Biologics
La Jolla Pharmaceutical Company*
Ligand Pharmaceuticals
Lithera
Lpath
Lumena Pharmaceuticals
MabVax Therapeutics
Mast Therapeutics
MEI Pharma
Meritage Pharma
Monsanto
Nautilus Environmental
NaZura BioHealth
NeuroGenetic Pharmaceuticals
Nitto Denko Technical
Novartis Pharmaceuticals
Noven Pharmaceuticals
Novo Nordisk
Nucelis
Ocera Therapeutics
Optimum Therapeutics
Orexigen Therapeutics
Otonomy
Pacira Pharmaceuticals
Panmira Pharmaceuticals
Pathway Genomics
Pfenex
PharmAkea
Polaris Group
Polynoma
PolyPeptide Group
Predictive Biology
Preventice
PrimaPharm
PrimeGen Biotech
Prognosys Biosciences
ProSci
QED Bioscience
Quanticel Pharmaceuticals
Receptos
Regulus Therapeutics
REKA Health
Rempex Pharmaceuticals
Renova Therapeutics
Ribomed Biotechnologies
Ridgeline Engineering
Roche Applied Science*
RQX Pharmaceuticals
RuiYi
Samumed
Sanguine BioSciences
Sanofi
Scripps Laboratories
Senju USA
Senomyx
Senté
Seragon Pharmaceuticals
SG Biofuels
Shin Poong Pharmaceutical Company
Sirenas Marine Discovery
Solstice Biologics
SoluLink
Sophiris Bio
Sorrento Therapeutics
SOVA Pharmaceuticals
Stemedica Cell Technologies
Sunovion Pharmaceuticals
Synthetic Genomics
Takeda Pharmaceuticals U.S.A.
Tanabe Research Laboratories
Tenova Pharmaceuticals
Thesan Pharmaceuticals
Tocagen
Tonbo Biosciences
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Triphase Accelerator
Trius Therapeutics
UCB
US Specialty Labs*
Vala Sciences
Vantari Genetics
Vaxiion Therapeutics
Verdezyne
Verenium
Vertex Pharmaceuticals
Vet-Stem
ViaCyte
Vical
Vital Therapies
Wellspring Biosciences
Wildcat Discovery Technologies
Zensun USA
Zogenix
CRO
Behavioral Pharma
Bend Research
BioAtla
CalChem Synthesis
Cato Research
Charles River Laboratories
ChemDiv
Concortis Biosystems
Cytelligen
Davos Chemical
Eastern Clinical Trials
EastHorn Clinical Services
Epistem
eStudySite
Exon BioSystems
Explora BioLabs
GENEWIZ
GRAM Laboratories
Hamari Chemical San Diego Research
Center
Huntingdon Life Sciences
Integrium Clinical Research
IriSys
JadeBio
MedinCell
MicroConstants
Molecular Response
MPI Research
Neuroservice*
OOxesis Biotech
PacificGMP
PharPoint Research*
Pharmatek Laboratories
PPD
Prescos
Profil Institute For Clinical Research
PSI CRO
Puracyp
Quadrants Scientific
RetroVirox
Reveal Biosciences
Rho
Robarts Clinical Trials
SAFC Pharma
SeqWright Genomic Services
Sherpa Clinical Packaging
Stemgent
SynteractHCR
Therapeutics, Inc.
Tioga Research
Toxikon
Triligent International
Ultimate Labs
Verum.us
Virapur
Wax-It Histology Services
Zyagen
AbbVie*
Ajinomoto Althea
Alexandria Real Estate Equities
Arena Pharmaceuticals
Bayer Healthcare
Biomed Realty Trust
Bioserv Corporation
Biospace
BP Biofuels
Abgent
Abide Therapeutics
Abwiz Bio
ACADIA Pharmaceuticals
ActivX Biosciences
Advanced BioMatrix
Advanced Targeting Systems
Aerie Pharmaceuticals
Afraxis
Aires Pharmaceuticals
Allylix
AM Chemicals
AMBRX
Amgen
Amicrobe
Amplyx Pharmaceuticals
Amylin Pharmaceuticals
AnaptysBio
AndroScience
Apricus Biosciences
Arcturus Therapeutics
Ardea Biosciences
Arrayomics
Astellas Pharma
aTyr Pharma
Auspex Pharmaceuticals
Avantgen
Avelas
Aviva Biosciences
Bachem Americas
BioLegend
Biomatrica
Biomyx
BioNano Genomics
Bionomics
Bio Options
BioSpyder Technologies*
BioTork
Abbiotec
Absorption Systems
Accelagen
Accugent Laboratories
Acurian
Advantar Laboratories
Agility Clinical
Alliance Protein Laboratories
Ambit Biosciences
American Peptide Company
AMRI
Annova Chem
ARIANNE
28
Medic al Device &
Diagnostic
Cell Idx
CeloNova BioSciences
Celula
Cliniqa Corporation
ClinMet
Compellon
CRISI Medical Systems
Critical Diagnostics
CTK Biotech
CVAC Systems
Cytori Therapeutics
DermTech International
DexCom
Diagnostic Consulting Network
Ellipse Technologies
Enigma Diagnostics
Entra Health Systems
Epic Sciences
Epitope Diagnostics
Fallbrook Engineering
FemCap
Fortimedix USA
Freedom Meditech
GenWay Biotech
Glaukos Corporation
Glysens
Hitachi Chemical Research Center
Ichor Medical Systems
Ignyta
ImpediMed
ImThera Medical
Inceptus Medical
INOVA Diagnostics
Interventional Spine
InVision Biomedical Group
Invivoscribe Technologies
Ionian Technologies
Ivantis
Ivera Medical
KFx Medical
Liferiver
MARDX Diagnostics
MD Revolution
Med Systems
Micell Technologies
Millennium Laboratories
Nano Imaging Services
OncoSec Medical
Organovo
Prometheus Laboratories
Qualigen
Quantum Design
Quidel
ReShape Medical
REVA Medical
Reverse Medical
ReVision Optics
Ridge Diagnostics
Roka Bioscience
Sequenom
Shire
Sienna Labs
Sirigen
Sonendo*
SpectraScience
Suneva Medical
Tandem Diabetes
Targeson
Tensys Medical
TherOx
Tristan Technologies
Trovagene
Uptake Medical
Valor Medical
VertiFlex
Yulex
Key Provider
Biotech Vending
BioTix
Blue Sky Broadcast
Bootstrap Incubation
Brinson Patrick Securities
Caliber Associates
California Commercial Security
Campbell Alliance
Canteen Vending Services
CB Richard Ellis
Cenduit
China Business Partners
Chubb Group of Insurance Companies
Clinigen Healthcare
Compete Consulting
Controlled Contamination Services
Cox Business*
Cymer
Domain Associates
EBD Group
Elsevier
Enterey
EquipNet
Euretos
Ferguson Pape Baldwin Architects
Fish & Richardson
Fisher & Phillips
Forward Ventures
French Biobeach*
Frequentz*
Gensler
Good & Roberts
Grande Colonial
Grant Thornton
HCP Life Science Estates
Hyatt Regency La Jolla at Aventine
Innovative Commercial Environments
Innovative Lease Services
J.T. MacMillan Photography
Jackson & Blanc HVAC Contractors
Jones Lang LaSalle*
KBM Facility Solutions
Kilroy Realty
Knobbe, Martens, Olson & Bear
Leadership Edge
Legacy Partners Commercial
Levementum
LG Technology Center of America
Managed Solution
Mayer Hoffman McCann
McKenna Long & Aldridge
Mission3
Morgan, Lewis & Bockius
Morrison & Foerster
Occupational Services
Office Depot
OfficeMax / Workplace Interiors
Ogletree, Deakins, Nash, Smoak &
Stewart
OmniComm Systems
Oxford Finance
Pegasus Cleanroom Services
Pharmalink Consulting
PR Newswire
Prevost Construction
Project Management Advisors
Prudential Cleanroom Services
Relocation Coordinates
Retirement DNA
San Diego World Trade Center
Sanford Rose Associates® - Toft Group
Sartorius
SecureDocs
Scient Federal Credit Union*
Sharp Business Systems
Sheppard Mullin Richter & Hampton
Shred San Diego
Silicon Valley Bank
SLM Group
Sofinnova Ventures
Sonceboz Corporation
Square 1 Bank
S Squared Executive Search*
Stradling Yocca Carlson & Rauth
Studley
Sughrue Mion
Technical Safety Services
The Business Cleaning Company
The HealthEd Group
The Sandler Group
Thomas, Mcnerney & Partners
T-Mobile USA
United Parcel Service (UPS)
Urban Contracting
VDP Direct
Veolia
Virgin America
Vision33
Human BioMolecular Research
Institute
Institute of Engineering in Medicine
ISM San Diego
J. Craig Venter Institute
Kaiser Permanente*
KOTRA - Los Angeles
La Jolla Bioengineering Institute
La Jolla Institute for Allergy &
Immunology
Lawrence Family Jewish Community
Center
Los Angeles Biomedical Research
Institute
MiraCosta College Biotech Program
Mt. San Jacinto College
PhRMA
Point Loma Nazarene University
Quebec Government
Rady School Of Management, UCSD
Salk Institute For Biological Studies
San Diego Clinical and Translational
Research Institute, UCSD
San Diego Community College District
San Diego Employers Association*
San Diego Natural History Museum
San Diego Regional Chamber of
Commerce
San Diego Regional Economic
Development Corp.
San Diego Supercomputer Center
(UCSD)
San Diego Workforce Partnership
San Diego Zoo Global
Sanford-Burnham Medical Research
Institute
Scottish Development International
Scripps Health
Scripps Research Institute
Swedish American Chamber Of
Commerce San Diego
The BioIndustry Association
The Lowy Medical Research Institute
(LMRI)
Torrey Pines Institute for Molecular
Studies
UC San Diego Extension
UCI’s Office of Research
UCSD, Department of Bioengineering
UCSD, External Relations Office
UCSD School of Medicine
UCSD, Technology Transfer Office
UK Trade & Investment
University of San Diego
Individual
Acon Laboratories
Aethlon Medical
Alphatec Spine
AltheaDx
America Diagnostics
Applied Proteomics
Astute Medical
Aviir
BeneChill
Biocept
BioDx
Biological Dynamics
bioTheranostics
Breathe Technologies
Bruin Biometrics
CareFusion
Airgas
Barney & Barney
Cushman & Wakefield
Oracle Health Sciences
Procopio, Cory, Hargreaves & Savitch
Qualcomm
San Diego Gas & Electric
Provider
2Connect
Accelrys
AIS (American Internet Services)
AlphaGraphics of La Jolla
AMN Healthcare
Assay Depot
Austin Commercial
Beckloff Associates
Bente Hansen & Associates
Bingham McCutchen
Bionest Partners
Biosources
BioSurplus
Biotech Primer
Non-Profit
American Cancer Society, Border
Sierra Region
American Red Cross - San Diego
CA Institute for Regenerative Medicine
Calibr
California Baptist University, College of
Engineering
California State University, San Marcos
City Of Murietta
CONNECT
Consulate Of Canada
CSU,CSUPERB Program
Escondido Union High School District*
Foundation For Personal Financial
Education
Antoinette Azevedo
Bernard King
Carol Gallagher*
Elliot Parks
Gary Friedman
John Kavanagh
Julie Ames
Larry Stambaugh
Peter Preuss
Richard Ledford
* New Members from October 2013 to January 2014
29
Prsrt Std
U.S. Postage
PAID
Permit #2325
San Diego, CA
4510 Executive Drive, Plaza One
San Diego, CA 92121-3021
www.Biocom.org
Please send a change of address
or subscription request to Katelyn
Doyle at [email protected].
3-DAY EVENT
Mammalian Fermentation Workshop
April 30-May 2, 2014 | 8:00 a.m. – 5:00 p.m. | UC San Diego Campus, La Jolla, CA
This 3-day workshop, developed in partnership between
UC San Diego’s Center for Continuing Education in
Biosciences (CCE|BIO) and UC San Diego Extension,
is designed to provide participants with a deeper
understanding of the performance of mammalian cell
culture operations throughout the product and process
life cycle from process development to full scale
manufacturing under current Good Manufacturing
Practices. This workshop combines practical knowledge
with case studies to provide participants with the ability
to thoroughly analyze experimental cell culture results.
• Learn about the history of mammalian cell
biotechnology and challenges faced
• Gain an overview of the manufacturing process
• Explore key issues and tools used in industrial cell
culture operations
• Develop a deeper understanding of technology
transfer and scale-up
SPEAKERS:
MICHAEL DAVID, PH.D.
Professor
Molecular Biology
UC San Diego
MICHAEL FINO, M.ENG.
Professor
Bioprocess Technology
MiraCosta College
MICHAEL
POHLSCHEIDT, PH.D.
Director
Manufacturing Operations
Genentech
ERIC M. FALLON, PH.D.
Director
Technology
Genentech
• Analyze experimental cell culture results using proper
statistical analysis
For more information and to register:
extension.ucsd.edu/lifesciences | (858) 534-9353 | [email protected]
Group Discounts Available!
Genentech
Site Visit
Included

lifeeasy

Transcription

Similar documents

Capuchinbird

Including, but not limited to, a choice of these items

4S Commons Town Center

Allen`s Swamp Monkey - San Diego Zoo Global Library

San Diego Wild Animal Park Water Master Plan

pp 1-3 Healing Waters Catalog

we`ve accomplished we`ve accomplished

Sudberry Properties Celebrates 30th Anniversary

2016 Coronation flyer short.psf

Layout 1 (Page 1) - Rescue Task Force